We developing long-acting injectable drugs for osteoarthritis. Our lead program is a 3-month extended-release formulation of celecoxib that can injected to arthritic joints quarterly. It has the potential to offer superior anti-inflammatory and pain relief than oral NSAIDs without carrying their systemic cardio-thrombotic and gastro-intestinal side effects. We have completed pre-IND meeting with the FDA and conducting GLP-toxicology studies.